Zacks Research Issues Positive Forecast for PCRX Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Analysts at Zacks Research increased their Q4 2026 earnings per share estimates for Pacira BioSciences in a research report issued on Tuesday, February 11th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.83 for the quarter, up from their prior forecast of $0.79. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.40 per share.

Other analysts also recently issued research reports about the stock. Royal Bank of Canada reiterated a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a report on Tuesday, January 14th. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their target price for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Needham & Company LLC lifted their price target on Pacira BioSciences from $22.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and set a $39.00 target price on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Finally, Barclays reduced their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $22.78.

Pacira BioSciences Trading Down 1.7 %

Shares of Pacira BioSciences stock opened at $26.78 on Thursday. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The stock has a fifty day simple moving average of $21.72 and a 200 day simple moving average of $18.06. Pacira BioSciences has a 12-month low of $11.16 and a 12-month high of $31.67. The company has a market capitalization of $1.24 billion, a P/E ratio of -13.25 and a beta of 0.80.

Hedge Funds Weigh In On Pacira BioSciences

Several large investors have recently modified their holdings of the business. Caitlin John LLC boosted its holdings in Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after buying an additional 1,776 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after acquiring an additional 2,749 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after acquiring an additional 513 shares during the period. Virtus Investment Advisers Inc. purchased a new position in shares of Pacira BioSciences in the third quarter valued at $98,000. Finally, CWM LLC raised its stake in shares of Pacira BioSciences by 713.6% during the 3rd quarter. CWM LLC now owns 6,517 shares of the company’s stock valued at $98,000 after purchasing an additional 5,716 shares during the period. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.